Life Technologies Corp and Boston Children’s Hospital have entered a research and development collaboration to develop an end-to-end genetic sequencing lab workflow based on Life Technologies’ Ion Proton™ Sequencer. The parties plan to collaborate and develop an optimized laboratory infrastructure and lab protocols for an advanced sequencing facility to be built at Boston Children’s in compliance with CLIA and CAP certification standards.
The collaboration expects to benefit from Life Technologies’ expertise in DNA sequencing technology and bioinformatics, and Boston Children’s clinical research, genomics and informatics expertise. David Margulies, director of The Gene Partnership Program at Boston Children’s Hospital said, "This collaboration is an important first step toward providing informed, personalized care for patients whose conditions are difficult to treat. The development of an optimized laboratory infrastructure will support our mission of providing the highest quality, innovative and cost effective care to our patients."
Paul Billings, chief medical officer at Life Technologies adds, "We are excited at the prospect of collaborating with the world-renowned experts in pediatric genetic disease at Boston Children’s to develop and demonstrate best practices for using our proprietary Ion Torrent sequencing platform. Partnerships like these are essential to our Medical Sciences strategy as we seek to assist researchers in discovering improved diagnostics and treatments for genetic conditions."
Ion Proton is for Research Use Only, not for use in diagnostic procedures.
Source: Life Technologies Corp
